AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed Hematologic Malignancy

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites๐Ÿ“ Phoenix๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Kura Oncology, Inc. ยท Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 260 sites๐Ÿ“ Huntsville๐Ÿ“ Phoenix๐Ÿ“ Scottsdale C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Dexamethasone TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site๐Ÿ“ Hangzhou Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-1942 Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma NCT05896228Phase 21 site๐Ÿ“ Miami Benjamin T Diamond, MD ยท Tests: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: PI3K inhibitor CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG-115, Azacitidine, Cytarabine Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate Universal CAR-T Cell Therapy for MM NCT07248176NA1 site๐Ÿ“ Shanghai Bioray Laboratories ยท Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Tampa Crossbow Therapeutics, Inc. ยท Tests: CBX-250 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites๐Ÿ“ Fukuoka๐Ÿ“ Sapporo๐Ÿ“ Kagoshima Otsuka Medical Devices Co., Ltd. Japan ยท Tests: Drug:5-ALA, Device:Photodynamic system CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites๐Ÿ“ Bullhead City๐Ÿ“ Los Angeles๐Ÿ“ Pembroke Pines GlaxoSmithKline ยท Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma NCT07760454Phase 1, Phase 22 sites๐Ÿ“ Suzhou๐Ÿ“ Shanghai UCARsgen Biotech Limited ยท Tests: CT0596 Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma NCT06245629n/a1 site๐Ÿ“ Uppsala Uppsala University ยท Tests: Bortezomib-bendamustine-melphalan Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies NCT07284927Phase 11 site๐Ÿ“ Suzhou PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310Phase 11 site๐Ÿ“ West Hollywood Oncotherapeutics ยท Tests: Selinexor, Ruxolitinib, Methylprednisolone Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084Phase 21 site๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Sorafenib A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252Phase 11 site๐Ÿ“ Atlanta OriCell Therapeutics Co., Ltd. ยท Tests: OriCAR-017 A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy NCT06756321EARLY Phase 11 site๐Ÿ“ Nantong Affiliated Hospital of Nantong University ยท Tests: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma NCT07333430Phase 11 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Naive HBI0101 CAR-T Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044Phase 116 sites๐Ÿ“ Phoenix๐Ÿ“ Orange๐Ÿ“ Jacksonville Jiangsu Simcere Pharmaceutical Co., Ltd. ยท Tests: SIM0500 Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse NCT05270200Phase 1, Phase 21 site๐Ÿ“ Guanzhou Zhujiang Hospital ยท Tests: Azacitidine, Chidamide A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma NCT07589634Phase 238 sites๐Ÿ“ Goodyear๐Ÿ“ Beverly Hills๐Ÿ“ Irvine Janssen Research & Development, LLC ยท Tests: Ramantamig, Tocilizumab, Placebo Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0) NCT07472972n/a1 site๐Ÿ“ Zurich University of Zurich Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies NCT06066203Phase 1, Phase 21 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: GNC-035 CAV Regimen for R/R AML NCT05657639Phase 21 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: CAV Regimen, MEC Regimen CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: CD70 CAR-NK
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy